Botanix Pharmaceuticals Limited AI Stock Analysis
Want to see AU:BOT full AI Analyst Report?
Botanix Pharmaceuticals Limited (BOT) AI Stock Analysis
Botanix Pharmaceuticals Limited
(ASX:BOT)
The score is mainly driven by weak financial quality (large, persistent losses and substantial cash burn despite strong revenue growth) and bearish technicals (price below major moving averages with negative MACD). Valuation contributes limited support because the company is loss-making (negative P/E) and no dividend yield is provided.
Botanix Pharmaceuticals Limited (BOT) vs. iShares MSCI Australia ETF (EWA)
- Market Cap
- AUD 21.92M
- Dividend Yield
- ―
- Average Volume (3M)
- 7.78M
- Price to Earnings (P/E)
- -0.3
- Beta (1Y)
- 1.04
- Revenue Growth
- 499.47%
- EPS Growth
- 31.20%
- Country
- Australia
- Employees
- 11
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Botanix Pharmaceuticals Limited Business Overview & Revenue Model
Company Description
Botanix Pharmaceuticals Limited, an Australian enterprise, is dedicated to the discovery and advancement of novel dermatological and antimicrobial therapeutic agents. The company's central mission involves pioneering innovative treatments for widespr...
Botanix Pharmaceuticals Limited Earnings Call Summary
The call conveyed strong commercial momentum — rapid prescription growth, meaningful revenue ramp, a high‑performing fulfillment platform (fill rates ~2.5x industry), positive physician adoption signals (90% expect to increase prescribing) and an attractive IP runway to 2040. Counterbalancing this progress are sizeable operating losses (adjusted EBITDA loss $26.1M; loss before tax $33.2M), material near‑term API purchase obligations and reliance on a partially‑completed capital raise and a single API supplier. Management has identified clear catalysts (alternate API supplier to cut COGS 25%–40%, platform scalability, and $45M committed raise) but execution and funding are key near‑term risks. Overall, the call was upbeat on commercial execution but sober about cash, supply and funding needs.
Q2-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Management guided that Botanix will scale Sofdra and its SendRx fulfillment platform while pursuing cost and supply improvements: since launch Sofdra has shipped 62,500 prescriptions (first 11 months) generating almost $100M gross revenue and $21.2M net revenue, and in H1 FY26 prescriptions rose 171% to 45,800 (from 16,800) with net revenue up 219% to $16.2M (total revenue $16.5M incl. royalties); fill/adherence metrics exceed industry benchmarks (~2.5x), the U.S. sales force is 50 reps (expanded Oct‑2025), cash was $31.6M at period end, adjusted EBITDA loss was $26.1M and loss before tax $33.2M, with materials $6.0M, sales & marketing $24.7M, employee costs $7.0M and G&A $3.2M. They have firm commitments for a $45M raise ($14.9M received) with proceeds allocated roughly $12M API/manufacturing, $4M alternate‑API setup, $13.5M marketing, $13M operating/working capital and $2.5M fees, are negotiating to defer near‑term API purchases (Mar/Apr 2026 and Jan 2027), and expect an alternate API to cut COGS 25–40% and improve gross‑to‑net toward ~30–40%; Sofdra’s IP runs to 2040 and the TAM is ~10M patients (≈3.7M actively seeking treatment), with management expecting revenue growth to outpace costs as adoption and payer coverage expand.
Botanix Pharmaceuticals Limited Financial Statement Overview
Summary
Revenue growth is strong (2026 up ~57% to ~34.5M), but profitability and cash generation are very weak. Gross profit turned deeply negative in 2026, EBIT and net income are materially negative, and operating/free cash flow remain heavily negative (large ongoing cash burn), implying continued reliance on external funding. The balance sheet is comparatively steadier with reduced debt and a remaining equity cushion, but ongoing losses pressure equity over time.
Income Statement
22NegativeBalance Sheet
54NeutralCash Flow
18Very Negative| Breakdown | TTM | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 34.51M | 34.51M | 5.79M | 601.82K | 914.97K | 2.75M |
| Gross Profit | -59.43M | -59.43M | 2.02M | -6.12M | -3.05M | -7.54M |
| EBITDA | -68.12M | -69.31M | -80.65M | -15.25M | -12.63M | -15.74M |
| Net Income | -69.77M | -69.77M | -86.40M | -13.87M | -9.15M | -13.17M |
Balance Sheet | ||||||
| Total Assets | 105.98M | 105.98M | 129.10M | 112.46M | 24.84M | 14.04M |
| Cash, Cash Equivalents and Short-Term Investments | 36.63M | 36.63M | 64.97M | 79.31M | 10.25M | 7.29M |
| Total Debt | 14.74M | 14.74M | 32.51M | 0 | 0 | 122.41K |
| Total Liabilities | 42.45M | 42.45M | 47.80M | 3.73M | 1.88M | 5.89M |
| Stockholders Equity | 63.52M | 63.52M | 81.30M | 108.73M | 22.95M | 8.15M |
Cash Flow | ||||||
| Free Cash Flow | -64.60M | -64.60M | -78.87M | -26.13M | -19.13M | -14.11M |
| Operating Cash Flow | -64.60M | -64.60M | -78.58M | -8.13M | -12.07M | -11.18M |
| Investing Cash Flow | -408.96K | -408.96K | -1.05M | -18.00M | -7.05M | -2.92M |
| Financing Cash Flow | 36.58M | 36.58M | 65.36M | 95.10M | 22.03M | -152.41K |
Botanix Pharmaceuticals Limited Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:BOT, the sentiment is Negative. The current price of 0.01 is above the 20-day moving average (MA) of 0.01, below the 50-day MA of 0.02, and below the 200-day MA of 0.03, indicating a neutral trend. The MACD of -0.00 indicates Negative momentum. The RSI at 33.47 is Neutral, neither overbought nor oversold. The STOCH value of 43.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:BOT.
Botanix Pharmaceuticals Limited Peers Comparison
Overall Rating
AU:CUV77Outperform
AU:ZLD52Neutral
AU:ACR47Neutral
AU:RCE46Neutral
AU:SPL43Neutral
AU:BOT42Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 77Outperform | AUD 372.59M | 10.85 | 13.00% | 0.68% | -1.05% | -6.74% | |
| 52Neutral | AUD 5.95M | -1.56 | 80.84% | ― | ― | ― | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 47Neutral | AUD 5.82M | -6.43 | -45.29% | ― | 290.25% | 92.05% | |
| 46Neutral | AUD 114.72M | -7.24 | 84.67% | ― | ― | 42.51% | |
| 43Neutral | AUD 200.41M | -24.27 | -42.35% | ― | 145.32% | 25.75% | |
| 42Neutral | AUD 27.63M | -0.31 | -118.74% | ― | 499.47% | 31.20% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| AU:BOT | Botanix Pharmaceuticals Limited | 0.01 | -0.11 | -91.67% | |
| AU:ACR | Acrux Limited | 0.01 | -0.00 | -33.33% | |
| AU:CUV | Clinuvel Pharmaceuticals Limited | 7.38 | -3.43 | -31.76% | |
| AU:SPL | Starpharma Holdings Limited | 0.41 | 0.02 | 5.33% | |
| AU:ZLD | Zelira Therapeutics Ltd. | 0.50 | 0.13 | 33.33% | |
| AU:RCE | Recce Pharmaceuticals Ltd. | 0.38 | -0.07 | -14.77% |
Botanix Pharmaceuticals Limited Corporate Events
Botanix Reports Cessation of 31.8 Million Securities
Botanix Pharmaceuticals Ltd reported the cessation of 31,816,666 conditional securities on November 1, 2026, comprising options and performance rights across five security classes. The securities lapsed because their conditions were not satisfied or...
Botanix sets 2026 AGM to vote on pay report and director re-election
Botanix Pharmaceuticals has called its annual general meeting for 30 November 2026 in Perth, where shareholders will review the company’s financial statements for the year ended 30 June 2026 and associated governance reports. The meeting will also co...
Botanix Pharmaceuticals Seeks ASX Quotation for New Share Issue
Botanix Pharmaceuticals has applied to the ASX for quotation of 1,125,000 new ordinary fully paid shares, to be issued on October 28, 2026. The additional securities arise from the exercise of options or conversion of other instruments, modestly incr...
Botanix’s Latest Investor Update Emphasises Risk and Regulatory Caution
Botanix Pharmaceuticals has released an investor update presentation dated 27 October 2026, outlining high-level information for current and prospective shareholders. The document is framed as a general summary, directing investors to ASX filings for...
Botanix Pharmaceuticals Appoints New Director With No Current Shareholdings
Botanix Pharmaceuticals Limited has appointed Mr Andrew Bickley as a director effective 18 October 2026, according to an initial director’s interest notice lodged with the ASX. At the time of appointment, Bickley holds no relevant interests in the co...
Botanix Discloses Director Daniel Sharp’s Exit and Indirect Holdings
Botanix Pharmaceuticals has disclosed that director Daniel Sharp ceased to be a director on 17 October 2026, in line with ASX listing rule requirements. The company reported that Sharp held no securities as a registered holder, but had indirect inter...
Botanix refreshes board with interim Australian directors after resignations
Botanix Pharmaceuticals has announced the immediate resignation of Australian resident Non-Executive Directors Dr Stewart Washer and Mr Danny Sharp, triggering a board renewal process at the dermatology-focused ASX-listed company. In response, Compan...
Botanix Sets 2026 AGM Date as Governance Milestones Align with Sofdra Push
Botanix Pharmaceuticals has scheduled its 2026 Annual General Meeting for 9:30 a.m. AWST on 30 November 2026 at BDO’s offices in Perth, Western Australia. The meeting will include the re-election of directors, with nomination deadlines set for 5:00 p...
Botanix Director Increases Equity Stake via Performance Rights Conversion
Botanix Pharmaceuticals has disclosed a change in director Vincent Ippolito’s interests, following the exercise of performance rights granted under the company’s employee incentive plan. Ippolito converted 4 million performance rights into fully paid...
Botanix seeks ASX quotation for 24.9 million new shares
Botanix Pharmaceuticals has applied for quotation on the ASX of 24,933,333 new ordinary fully paid shares, which were issued on 22 September 2026. The application indicates an expansion of the company’s listed share capital, potentially providing add...
S&P Dow Jones Indices Unveils September 2026 Rebalance of S&P/ASX Benchmarks
S&P Dow Jones Indices has announced its September 2026 quarterly rebalance of the S&P/ASX indices, with changes taking effect before trading opens on September 21. The S&P/ASX 20 will remain unchanged, while the S&P/ASX 50 will see Mineral Resources...
Botanix Updates Director Patricia Walker’s Equity Holdings After Option Expiry
Botanix Pharmaceuticals has disclosed a change in director Dr Patricia Walker’s interests, following the expiry and cancellation of 1,000,000 unquoted options exercisable at $0.145 that were due to expire on 22 August 2026. After the change, Dr Walke...
Botanix Pharmaceuticals Options Lapse, Streamlining Capital Structure
Botanix Pharmaceuticals Ltd has reported the lapse of 1,000,000 options, each exercisable at $0.145 and expiring on 22 August 2026, which ceased on 25 August 2026 after remaining unexercised. The expiry modestly reduces the company’s pool of potentia...
Botanix files updated ASX corporate governance statement for 2026
Botanix Pharmaceuticals has lodged its updated corporate governance statement for the financial year ended 30 June 2026, confirming it is available on the company’s website and has been approved by the board as at 26 August 2026. The accompanying App...
Botanix Revenue Surges on Sofdra Launch as Loss Narrows
Botanix Pharmaceuticals reported a sharp increase in revenue for the year ended 30 June 2026, with customer sales rising 487% to $33.8 million, driven by the first full year of Sofdra’s commercial launch in the United States and royalty income from p...
Botanix Issues 14 Million Unquoted Performance Rights Under Incentive Plan
Botanix Pharmaceuticals has notified the market of the issue of 14,000,000 unquoted performance rights under its employee incentive scheme. The new securities, which are not intended to be quoted on the ASX, were issued on August 11, 2026 and undersc...
Botanix Pharmaceuticals Adds 2.3 Million Shares to ASX Quotation
Botanix Pharmaceuticals has applied for quotation of 2,300,000 additional ordinary fully paid shares on the ASX, with an issue date of Aug. 13, 2026. The application is lodged under Appendix 2A of the ASX Listing Rules, confirming the securities will...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 07, 2026
